- 现金
- 62111 元
- 精华
- 26
- 帖子
- 30437
- 注册时间
- 2009-10-5
- 最后登录
- 2022-12-28
|
Therapeutic efficacy of lenvatinib in nonviral unresectable hepatocellular carcinoma
Tetsu Tomonari 1 , Yasushi Sato 2 , Hironori Tanaka 1 , Takeshi Mitsuhashi 1 , Akihiro Hirao 1 , Takahiro Tanaka 1 , Tatsuya Taniguchi 1 , Koichi Okamoto 1 , Masahiro Sogabe 1 , Hiroshi Miyamoto 1 , Naoki Muguruma 1 , Tetsuji Takayama 1
Affiliations
Affiliations
1
Department of Gastroenterology and Oncology, Institute of Biomedical Sciences Tokushima University Graduate School Tokushima Japan.
2
Department of Community Medicine for Gastroenterology and Oncology Tokushima University Graduate School of Biomedical Sciences Tokushima Japan.
PMID: 34816013 PMCID: PMC8593789 DOI: 10.1002/jgh3.12663
Free PMC article
Abstract
Aim: To investigate the therapeutic effect of lenvatinib (LEN) in liver disease etiology, especially nonviral hepatocellular carcinoma (HCC).
Methods and results: Sixty-seven patients with unresectable advanced HCC (u-HCC) treated with LEN and consisting of 26 hepatitis C virus (HCV), 19 hepatitis B virus (HBV), 11 alcohol, and 11 nonalcoholic steatohepatitis (NASH) cases were retrospectively recruited. Univariate and multivariate Cox proportional hazard models were used to determine predictive factors for survival. The objective response rate in the nonviral (alcohol and NASH) group was higher than that in the viral group (59.1% [13/22] vs. 46.7% [21/45]). Progression-free survival was significantly longer in the nonviral group than in the viral group (13.7 vs. 6.6 months; hazard ratio [HR] 0.324; 95% confidence interval [CI] 0.174-0.602; P < 0.01). Similarly, median overall survival (OS) was significantly longer in the nonviral group than in the viral group (not evaluable vs. 15.9 months; HR = 0.277; 95% CI = 0.116-0.662; P < 0.01). Multivariate analysis revealed that portal vein invasion (HR = 5.327, P = 0.0025), treatment line (HR = 0.455, P = 0.023), and etiology (HR = 0.180, P = 0.00055) were significant independent factors associated with OS in u-HCC patients treated with LEN.
Conclusion: Our results suggest that LEN is more effective against nonviral u-HCC than against viral u-HCC.
Keywords: atezolizumab; bevacizumab; lenvatinib.
© 2021 The Authors. JGH Open published by Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd. |
|